IPP Bureau
Lonza partners with biotech firm HaemaLogiX on multiple myeloma drug candidate
By IPP Bureau - January 29, 2022
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
Lupin signs promotional agreement with Exeltis on SOLOSEC
By IPP Bureau - January 28, 2022
SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment
European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC
By IPP Bureau - January 28, 2022
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
Biogen sells equity stake in its biosimilar JV with Samsung Biologics for US $ 2.3 billion
By IPP Bureau - January 28, 2022
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
Moderna working on HIV vaccine antigens delivered through mRNA technology
By IPP Bureau - January 28, 2022
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
HealthPlix is in NASSCOM’s `League of 10’ companies 2021
By IPP Bureau - January 28, 2022
The award was given as a result of NASSCOM's meticulous screening process, in which over 700 start-ups were shortlisted as the most promising companies of the year
Granules receives ANDA approval for potassium chloride for oral solution USP, 20 mEq
By IPP Bureau - January 28, 2022
Potassium chloride is used to prevent or to treat low blood levels of potassium
Glenmark Pharmaceuticals receives ANDA approval for metronidazole vaginal gel, 0.75%
By IPP Bureau - January 28, 2022
Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA
Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.
By IPP Bureau - January 28, 2022
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021
Covaxin and Covishield granted conditional market approval
By IPP Bureau - January 27, 2022
The vaccines are currently only authorised for emergency use in the country
Moderna working on Omicron-specific booster candidate
By IPP Bureau - January 27, 2022
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
Mark Cuban’s online pharmacy set to disrupt drug prices in the US
By IPP Bureau - January 27, 2022
Direct to consumer pharmacy and formation as pharmacy benefit manager further mission to drastically expand access to affordable pharmaceuticals
Thermo Fisher Scientific earns NSF/ANSI 456 vaccine storage certification
By IPP Bureau - January 27, 2022
It meets stringent requirements for ensuring the safe storage and efficacy of temperature-sensitive vaccines, including those for Covid-19
Sun Pharma launches ophthalmic solution in Canada
By IPP Bureau - January 27, 2022
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
Glenmark receives ANDA approval for hydrochlorothiazide tablets
By IPP Bureau - January 27, 2022
According to IQVIA sales data for the 12-month period ending November 2021, the Ziac tablets, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg market achieved annual sales of approximately US $ 30.3 million
